News

Hope for patients with Catel-Manzke syndrome

This major breakthrough will provide new insights into bacterial defense mechanisms and enable the development of new antibiotics.

On February 24th, she enlightened us on the molecular and cellular basis of T-cell tolerance.

PREDATOR gives way to VAMPIRE

Taking pneumococcus out of the zoo

A discovery by the group of Benoit Van den Eynde

The Gagna & Van Heck International Prize for incurable diseases is awarded for the first time to a Belgian team.

Also if the disease starts at a later age, the cause may be genetic

A discovery by Takfarinas Kentache, Emile Van Schaftingen and Guido Bommer

Thanks to all supporters for our first 20 km team!

Program

Her Majesty Queen Mathilde presented the prize for groundbreaking results in the field of cancer immunotherapy

Celebrate our double anniversary with us !

Prof. Miikka Vikkula has received the Lifetime Achievement Award in Lymphatic Research during the Gordon Research Conference on Lymphatics in Ventura, USA. The prize is awarded every two years by the Lymphatic Education and Research Network (LE&RN).

Modulation of the thrombopoietin receptor conformation allows targeted inhibition of malignant cells in myeloproliferative neoplasms

Pascale Cossart enlightens us on the molecular and cellular bases of bacterial infections.

The result of a collaboration between researchers at the de Duve Institute and the Institute of Neuroscience.

Some insight from our IT

Nature journal highlights de Duve Institute research:
an innovative approach that could improve the efficacy of cancer immunotherapy

World first: treatment of a vascular malformation in utero

Don't miss the annual gala evening of the de Duve Institute, on October 12.

Program

Elucidating how mutations in a chaperone, calreticulin, induce blood cancer

From the laboratory to the auditorium:
the UCLouvain discovery in the world's biochemistry books.

Best practices for single-cell proteomics

Miikka Vikkula is the 2023 Recipient of the Earl P. Benditt Award
of the North American Vascular Biology Organization (NAVBO)

An immunotherapy proves to be effective against certain blood cancers

From Neanderthals to COVID-19: genetic and evolutionary
sources of human immune response variation

"Checkmate disease"

"Win (Wnt) your hair back":
a novel role of a Wnt receptor, ROR2, in regulating skin stem cells

New treatment for a severe vascular disease proves effective:
Promising results after using thalidomide in clinical trial

Program

Nick van Gastel receives the FNRS Lambertine Lacroix Prize

Guido Bommer receives the Viscountess Valine de Spoelberch Prize 2022 from the Queen Elisabeth Medical Foundation

$7 million for vascular malformation research from the Leducq Foundation.
Transatlantic collaboration with Miikka Vikkula as European coordinator

Genetic cause found for a severe form of lymphedema

Sophie Lucas, holder of a Francqui Chair, at the invitation of the Faculty of Medicine of the University of Namur

Different pathogens use the very same trick, yet to escape
different effectors of the immune response

PARK7, an enzyme involved in the metabolism of sugars,
is inactive in some patients with Parkinson's disease

Many fellowships, grants and credits obtained from the FNRS in 2021!

Prof. Thierry Boon has been honored by a DHC from VUB

Clap for Research: Together for basic research

This important prize is awarded every three years to French- and Flemish-speaking researchers in support of their cancer research.

More bacterial than human

Inactivation of the PDGFRB gene by mutations in primary familial brain calcification

A discovery by the group of Miikka Vikkula gives insight in the pathogenesis of Gorham-Stout disease and provides a lead for a possible drug therapy

The soft spaghetti of proteins, essential for the resistance of bacteria

A better understanding of KRAS-driven pancreatic cancer initiation

Program of the 2021 online edition

Asma Boujtat is Ambassador of Sciences 2021 !

"Bacteria research" appeals to Japan

A discovery by the team of Jean-Francois Collet

A discovery by Miikka Vikkula and his team as part of an international collaboration

On January 5, 2021, the Belgian SARS-Covid vaccination campaign began. Our experts take a look.

Two researchers receive an FNRS award

A discovery by Jean-François Collet and his collaborators

A discovery by the teams of Jean-François Collet and Yves Dufrêne

Following the discovery of the mechanism of the disease by Veiga-da-Cunha, Van Schaftingen and their collaborators

Their difficult development explained by Thomas Michiels, who studies a promising avenue of research

Thomas Michiels describes the origins and the characteristics of this virus

awarded to Sophie Lucas for her work on cancer immunotherapy

a discovery by Pierre Courtoy and his team

For almost 15 years, Anabelle Decottignies and her team have been studying telomeres

Patrick Jacquemin's group identifies an important signaling pathway for the development of initiating lesions

A study by Claude Gérard, Mickael Di-Luoffo, Léolo Gonay, Frédéric Lemaigre and coworkers

organized early July 2019 by Laurent Gatto, Jean-Baptiste Demoulin and Axelle Loriot

Failure to eliminate a phosphorylated glucose analog
leads to neutropenia in patients with G6PT and G6PC3 deficiency

awarded to Miikka Vikkula for his work on vascular anomalies

It will fund research from Géraldine Laloux on a small bacterium with an atypical life cycle

The group of Sophie Lucas shows how an antibody glues an inhibitory messenger on immunosuppressive cells

Thomas Michiels and groups from three other universities will study how viruses bypass immune defenses

7 academic groups and 2 companies join forces to study the molecular mechanisms causing vascular anomalies

A discovery by Jean-Francois Collet and Camille Goemans

iTeos is a biotech spin-off developing cancer discoveries from the de Duve Institute

to Anabelle Decottignies for her work on telomeres and its possible applications to cancer

Prof. Van den Eynde’s team is contributing to EU project MESI-STRAT

by Jean-Francois Collet and his team

awarded to Anabelle Decottignies for her work on telomeres

An ERC Consolidator Grant rewards Guido Bommer's research

awarded to Stefan Constantinescu for his work on the physiopathology of myeloproliferative syndromes

How antibodies against integrins block immunosuppression by Tregs, a discovery by Sophie Lucas' team

identified by the group of Benoit Van den Eynde

New discovery in tumor immunology by the group of Pierre van der Bruggen

Identification of a new regulator of liver development by the group of Frédéric Lemaigre

a discovery by the team of Jean-Baptiste Demoulin

discovered by Mustapha Amyere, Nicole Revencu, Raphaël Helaers, Miikka Vikkula and Laurence Boon

A collaboration between UCL, ULB, ULg and iTeos Therapeutics, coordinated by Pierre Coulie

A discovery by Anabelle Decottignies, Nicolas van Baren & Christophe Pierreux

for her work on venous malformation

Recent finding by Patrick Jacquemin and his team

A discovery by the team of Pierre van der Bruggen

A study by Miikka Vikkula and collaborators

A discovery by Anabelle Decottignies

Discovery of a new post-translational modification in eukaryotes

Results obtained by C. Pierreux and his team

Discovery by Professor Mark Rider and his team

The European Research Council will fund research from S. Lucas

Results published by J.-F. Collet and F. Barras in the prestigious journal Nature

Discovery by the teams of Prof. M. Vikkula and Prof. L. Boon

Discovery by Prof. J.-B. Demoulin and Coworkers

SH Cho and JF Collet, with two groups at Harvard Medical School, report the structure of the membrane protein CcdA.

Sophie Lucas and her team show how a new antibody increases cancer immunotherapy efficiency

The groups of M. Vikkula & L. Boon discovered a drug against venous malformations.

The group of S. Lucas proposes a new therapeutic approach to stimulate tumor cell destruction by the immune system.

The group of J.-F. Collet discovers a new stress sensing mechanism in bacteria. Published in Cell.

SOX9 regulates ERBB signalling in pancreatic cancer development.

A discovery from the group of Thomas Michiels was recently published in the Journal of Virology.